Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, has scheduled its second quarter 2025 financial results announcement for August 11, 2025.
The company will host a video conference call and webcast at 8:30 a.m. ET on the same day. Interested parties can register for the video call and access the webcast through a provided link or by visiting the "News and Events" section in the Investors area of Kymera's website.
Kymera Therapeutics (NASDAQ: KYMR), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di farmaci orali a piccole molecole degradanti per malattie immunologiche, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 11 agosto 2025.
La società terrà una teleconferenza video e una webcasting alle 8:30 a.m. ET dello stesso giorno. Gli interessati possono registrarsi per la videochiamata e accedere alla webcasting tramite un link fornito o visitando la sezione "News and Events" nell'area Investitori del sito web di Kymera.
Kymera Therapeutics (NASDAQ: KYMR), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos orales con pequeñas moléculas degradadoras para enfermedades inmunológicas, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 11 de agosto de 2025.
La compañía realizará una videoconferencia y una transmisión en vivo a las 8:30 a.m. ET el mismo día. Las personas interesadas pueden registrarse para la videollamada y acceder a la transmisión a través de un enlace proporcionado o visitando la sección "Noticias y Eventos" en el área de Inversores del sitio web de Kymera.
Kymera Therapeutics (NASDAQ: KYMR)는 면역 질환을 위한 경구용 소분자 분해제 약물 개발에 주력하는 임상 단계의 바이오제약 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 11일로 예정했습니다.
회사는 같은 날 동부 표준시 오전 8시 30분에 화상 회의 및 웹캐스트를 개최할 예정입니다. 관심 있는 분들은 제공된 링크를 통해 또는 Kymera 웹사이트 투자자 섹션 내 '뉴스 및 이벤트'에서 등록하여 화상 통화에 참여하고 웹캐스트에 접속할 수 있습니다.
Kymera Therapeutics (NASDAQ: KYMR), une société biopharmaceutique en phase clinique spécialisée dans le développement de médicaments oraux à petites molécules dégradantes pour les maladies immunologiques, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 11 août 2025.
La société organisera une conférence téléphonique vidéo et une webdiffusion à 8h30 ET le même jour. Les personnes intéressées peuvent s'inscrire à l'appel vidéo et accéder à la webdiffusion via un lien fourni ou en visitant la section « Actualités et Événements » dans la zone Investisseurs du site Web de Kymera.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung oraler Wirkstoffe zur Molekül-Degradierung bei immunologischen Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 11. August 2025 terminiert.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Videokonferenz und einen Webcast veranstalten. Interessierte können sich für den Videoanruf registrieren und über einen bereitgestellten Link oder im Bereich „News und Events“ im Investorenbereich der Kymera-Website auf den Webcast zugreifen.
- None.
- None.
WATERTOWN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2025 financial results on August 11, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
When will Kymera Therapeutics (KYMR) report Q2 2025 earnings?
What time is Kymera Therapeutics' Q2 2025 earnings call?
How can investors access Kymera Therapeutics' Q2 2025 earnings call?
What type of medicines is Kymera Therapeutics (KYMR) developing?
